An analyst sees good growth prospects for Aclaris Therapeutics Inc (ACRS)

With 0.63 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.99 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $1.24 whereas the lowest price it dropped to was $1.17. The 52-week range on ACRS shows that it touched its highest point at $11.12 and its lowest point at $0.59 during that stretch. It currently has a 1-year price target of $1.84. Beta for the stock currently stands at 0.10.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ACRS was down-trending over the past week, with a drop of -11.94%, but this was down by -2.48% over a month. Three-month performance surged to 0.85% while six-month performance fell -75.18%. The stock lost -85.04% in the past year, while it has gained 12.38% so far this year. A look at the trailing 12-month EPS for ACRS yields -1.09 with Next year EPS estimates of -0.63. For the next quarter, that number is -0.20. This implies an EPS growth rate of 37.10% for this year and 21.28% for next year.

Float and Shares Shorts:

At present, 70.89 million ACRS shares are outstanding with a float of 65.00 million shares on hand for trading. On 2024-04-30, short shares totaled 5.95 million, which was 834.0 higher than short shares on 1711584000. In addition to Dr. Neal S. Walker D.O., M.D. as the firm’s Co-Founder, President, Chairman & Interim CEO, Mr. Kevin Balthaser serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 0.91379 of ACRS’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-03-31, ACRS reported revenue of $2398000.0 and operating income of -$16131000.0. The EBITDA in the recently reported quarter was -$13088000.0 and diluted EPS was -$0.24.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ACRS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.